In the present study, we demonstrate that sorafenib treatment leads to the downregulation of Arg2 at the mRNA and protein expression levels, which suppresses ferroptosis by activating the Akt/GPX4 signaling pathway in mouse melanoma cells. This evidence concerns the gene GPX4 and melanoma.